Expanded collaboration to allow higher biopharmaceutical entry to Personalis (NASDAQ:) MRD resolution
FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) right this moment introduced that the businesses have expanded their enterprise relationship. The businesses agreed in November 2023 to collaborate and commercialize the ultra-sensitive MRD assessments and launched their efforts on the 2024 American Society of Scientific Oncology (ASCO) Annual Assembly. Tempus is the unique diagnostic advertising and marketing associate for Personalis’ ultra-sensitive tumor-based MRD product, NeXT Private ® Dx, for broad adoption amongst sufferers with breast and lung cancers, and for immunotherapy monitoring in all stable tumors.
Following a optimistic response from the diagnostics market, the businesses agreed to broaden their relationships with the biopharmaceutical trade. As a part of this expanded relationship, Tempus will have the ability to supply Personalis’ NeXT Private MRD product to pharmaceutical and biotechnology prospects who want to bundle MRD testing with different Tempus choices in a given examine.
Whereas we already supply NeXT Private via our personal biopharma channel, we’re excited to additionally leverage Tempus’ built-in platform for biopharma prospects who wish to mix NeXT Private with different Tempus merchandise, stated Chris Corridor, CEO of Personalis . We imagine that increasing the connection with Tempus will speed up the market penetration of our main ultra-sensitive MRD platform and permit us to raised capitalize on this chance.
About Personalis, Inc.
At Personalis, we’re remodeling lively most cancers administration with groundbreaking personalised testing. We intention to create a brand new paradigm for most cancers administration, guiding care from biopsy all through the affected person’s life. Our extremely delicate assessments mix tumor and regular profiling with proprietary algorithms to supply superior data even because the most cancers progresses over time. Our merchandise are designed to detect minimal residual illness (MRD) and recurrence as early as potential, allow number of focused therapies primarily based on ultra-comprehensive genomic profiling, and enhance biomarker technique for drug improvement. Personalis relies in Fremont, California. To study extra, go to www.personalis.com and join with us on LinkedIn and X, previously generally known as Twitter.
Ahead-looking statements
This press launch comprises forward-looking statements throughout the which means of the Non-public Securities Litigation Reform Act of 1995. Any statements contained on this press launch that aren’t historic are forward-looking statements throughout the which means of america securities legal guidelines, together with together with statements regarding attributes or a possibility for NeXT Private or the anticipated advantages of the expanded relationship with Tempus. These forward-looking statements contain identified and unknown dangers and uncertainties and different components which will trigger precise outcomes to vary materially from anticipated outcomes or expectations expressed or implied by such statements, together with dangers, uncertainties and different components associated to the success of Tempus’ gross sales and advertising and marketing efforts, together with the anticipated acceleration of NeXT Private’s market penetration. These potential dangers and uncertainties, in addition to different dangers and uncertainties that would trigger precise outcomes to vary materially from the outcomes anticipated in such forward-looking statements, are described beneath the headings Threat Components and Administration’s Dialogue and Evaluation. monetary situation and outcomes of operations from Personalis’ Annual Report on Type 10-Ok for the 12 months ended December 31, 2023, filed with the Securities and Change Fee (SEC) on February 28 2024, its Quarterly Report on Type 10-Q for the quarter ended March 31, 2024, filed with the SEC on Could 8, 2024, its Quarterly Report on Type 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 7, 2024, and its Quarterly Report on Type 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. All data supplied on this launch is as of the date of this press launch, and all forward-looking statements contained herein are primarily based on assumptions that we imagine to be cheap as of such date. Undue reliance shouldn’t be positioned on the forward-looking statements contained on this press launch, that are primarily based on data out there to us as of the date hereof. Personalis assumes no obligation to replace this data, besides as required by legislation.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241216417697/en/
Buyers:
Caroline Coin
traders@personalis.com
415-202-5678
Media Contact:
Patrick Schmidt
pr@personalis.com
630-290-2787
Supply: Personnel, Inc.
#Personalis #Tempus #broaden #collaboration #biopharmaceutical #sector #Investing.com , #Gossip247
,
